MicroalbuminuriaDIGICARE-DREAMNCT07588256
New Taipei City 888 Digital Medical AI Platform for Prevention and Care of the Three Highs and Cardio-Renal-Vascular Diseases
A study testing Interactive digital modules and Antihypertensive Medication Management in people with Microalbuminuria and Microalbuminuria /Creatinine Ratios ACR, run by New Taipei City Medical Association at 1 site in Taiwan.
Trial summary
Non-communicable diseases (NCDs), or chronic diseases, are a major public health burden globally and in Taiwan, and control of the "three highs" (hypertension, dyslipidemia, and hyperglycemia) is a national priority. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Microalbuminuria, Microalbuminuria /Creatinine Ratios ACR, Cardiovascular Disease Risk Factor
- What is being tested?
- Interactive digital modules and Antihypertensive Medication Management
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4,162 participants
- Where
- 1 siteTaiwan
- Study dates
- 5 Feb 2026to 5 Feb 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- I.T-888-DIGICARE：
- Eligible participants must meet the definition of hypertension and at least one of the following chronic (non-hypertensive) conditions:
- Hypertension
- With or without treatment, and meeting one of the following:
- Office blood pressure: two consecutive measurements >130/80 mmHg
- Home blood pressure: weekly average (morning/evening) >130/80 mmHg, or more than half of the weekly measurements exceeding this threshold
Show all 41Show fewer
- Hyperlipidemia
- With or without treatment, and
- LDL-C >100 mg/dL (or >70 mg/dL in patients with diabetes or established ASCVD)
- Diabetes Mellitus
- With or without treatment, and
- HbA1c >6.5%
- Chronic Kidney Disease (CKD)
- Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m², and
- Urine albumin-to-creatinine ratio (UACR) >30 mg/g
- Atherosclerotic Cardiovascular Disease (ASCVD):
- Including coronary artery disease, cerebrovascular disease, peripheral arterial disease, or aortic pathology
- DREAM-G:
- Hypertension
- With or without treatment, and meeting one of the following:
- Office blood pressure: two consecutive measurements >130/80 mmHg
- Home blood pressure: weekly average (morning/evening) >130/80 mmHg, or more than half of weekly measurements exceeding this threshold
- Hyperlipidemia
- With or without treatment, and
- LDL-C >100 mg/dL (or >70 mg/dL in patients with diabetes or established ASCVD)
- Diabetes Mellitus
- With or without treatment, and
- HbA1c >6.5%
- Chronic Kidney Disease (CKD)
- Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m², and
- Measurable urinary microalbumin-to-creatinine ratio
- Atherosclerotic Cardiovascular Disease (ASCVD):
- Including coronary artery disease, cerebrovascular disease, peripheral arterial disease, or aortic pathology
- Participants must meet at least one of the above chronic disease conditions and:
- Untreated Hypertension:
- Morning home blood pressure (HBP) >130/80 mmHg: weekly average (≥4 days) >130/80 mmHg,
- Or more than half of morning HBP measurements (≥4 days per week) >130/80 mmHg
- Treated Hypertension:
- Morning home blood pressure >130/80 mmHg: weekly average (≥4 days) >130/80 mmHg,
- Or more than half of morning HBP measurements (≥4 days per week) >130/80 mmHg
- Average home blood pressure ≤130/80 mmHg (used to determine treatment strategy)
Who cannot join
- T-888-DIGICARE
- Symptomatic heart failure (New York Heart Association functional class II-IV)
- End-stage renal disease requiring long-term dialysis
- Pregnant women or those planning pregnancy
- DREAM-G:
- Life expectancy <1 year
Show all 9Show fewer
- End-stage renal disease (ESRD) requiring regular renal replacement therapy, including dialysis, kidney transplantation, or palliative care
- Severe liver cirrhosis
- Malignancy under active treatment
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Tzung-Dau Wang Co-Principal Investigator contact
Taiwan1 site, 1 recruiting
- Recruiting
United safety medical group(USMG)
New Taipei City
Lian An Clinic, 886-22998-6191, usmg@usmg.com.tw
Smart Health Technology Research and Development Center, NTU, 886-2-33669118
About this study
Official title: New Taipei City 888 Digital Medical AI Platform for the Prevention and Treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia) and Cardio-Renal-Vascular Diseases: Validation and Implementation Through Large-Scale Cluster Randomized Clinical Trials: T-888-DIGICARE-DREAM
Non-communicable diseases (NCDs), or chronic diseases, are a major public health burden globally and in Taiwan, and control of the "three highs" (hypertension, dyslipidemia, and hyperglycemia) is a national priority. Nearly half of the 10 leading causes of death in Taiwan are directly or indirectly related to atherosclerotic cardiovascular disease (ASCVD), for which hypertension, dyslipidemia, and abnormal blood glucose are the major risk factors. National health insurance data indicate that over 70% of middle-aged and older adults have at least one of these chronic conditions. Early stages are often asymptomatic, and inadequate control may lead to complications of cardiovascular disease, stroke, renal vascular disease, and retinopathy, causing irreversible organ damage and death.
For blood pressure, large clinical trials such as SPRINT and STEP have shown that targeting systolic blood pressure below 130 mmHg significantly reduces ASCVD events. For LDL cholesterol, "the lower, the better" applies, with guideline-recommended LDL-C targets determined by baseline ASCVD risk, with levels below 55 mg/dL for very high-risk patients. For diabetes, treatment goals generally include fasting plasma glucose below 130 mg/dL and glycated hemoglobin (HbA1c) below 7%.
Read more
Although antihypertensive therapy has been proven effective in preventing cardiovascular disease and chronic kidney disease attributable to hypertension, fewer than one-third of patients receiving antihypertensive medications achieve current guideline-recommended blood pressure targets. No randomized clinical trial to date has used home blood pressure as the primary therapeutic reference. Moreover, long-term evidence is lacking regarding the organ-protective effects of strategies targeting morning hypertension and of bedtime dosing regimens. Although the TIME study is currently the largest and longest-followed trial addressing dosing time, its bedtime-dosing arm was not specifically targeted to patients with morning hypertension. Therefore, we propose a clinical trial to investigate management strategies for morning hypertension. Aligned with the 2022 Taiwan Hypertension Guidelines, we will employ the "722 protocol" for home blood pressure monitoring and enroll patients with morning home blood pressure ≥130/80 mmHg to compare selective nocturnal administration of antihypertensive agents versus exclusive morning dosing, assessing differences in morning home blood pressure control rates, end-organ damage, and atherosclerotic cardiovascular disease (ASCVD) events.
This project will implement two large-scale cluster-randomized clinical trials within the New Taipei City healthcare network. The first trial (T-888-DIGICARE) will evaluate whether a mobile digital health platform augmented with interactive digital modules can more effectively achieve the "888" targets for prevention and treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia). The second trial (DREAM-G) will use the same mobile health delivery model to investigate whether the timing of antihypertensive medication administration (nocturnal versus morning dosing) differentially affects patients with poor morning home blood pressure control. Beyond generating rigorous evidence through a novel clinical approach, this program is expected to have substantial global clinical impact and to showcase Taiwan's healthcare capabilities internationally. Operational challenges encountered and solutions developed during the trials will also provide critical feasibility data for the concurrent real-world implementation registry (T-888-DIGICARE-Registry). The registry will run in parallel with the cluster trials and will enroll individuals who decline trial participation at baseline as well as participants after trial completion, thereby serving as a continuity and real-world evidence platform.
Read the detailed description
Participants identified through the 888 screening program with at least one abnormal value will be invited for group allocation. Home blood pressure measurement will be performed according to the "722 protocol." If morning home BP ≥130/80 mmHg (average home BP ≥130/80 mmHg or already receiving antihypertensive therapy), participants will be invited to join the randomized clinical trial DREAM-G, investigating optimal timing of antihypertensive medication for morning hypertension. All other participants will be invited to the randomized clinical trial T-888-DIGICARE, evaluating care intervention via a mobile smart healthcare platform. Those not enrolled will be invited to participate in the pragmatic digital health registry program T-888-DIGICARE-Registry.
Execution methods and procedures for these three large-scale clinical trials are as follows:
Randomized Clinical Trial of Mobile Smart Healthcare Platform Intervention (T-888-DIGICARE)
- Randomization Unit: Participating primary care clinics. Each clinic must complete informed consent and enrollment preparation prior to participation.
- Randomization Method: Computer-generated block randomization, stratified by clinic location. Stratification is based on the median household disposable income across the 29 administrative districts of New Taipei City, categorized into three socioeconomic tiers. Clinics are randomized within each tier to minimize confounding by socioeconomic status on health behaviors and healthcare accessibility, and to facilitate future policy expansion in lower-income regions.
- Given the practical nature of digital platform implementation, blinding of physicians and patients is not feasible. Therefore, a single-blind design is adopted: investigators responsible for data aggregation and statistical analysis of primary and secondary endpoints remain blinded to clinic allocation, reducing analytic bias.
- Intervention Measures:
- Years 1-5 (Trial duration: 3 years enrollment, 2 years follow-up)
- Intervention group: Comprehensive integration of the "888 Digital Management Platform" into participating clinics and patient mobile devices. Features include app-based interactive modules, personalized message push notifications, input of "three-high" (hypertension, hyperlipidemia, hyperglycemia) test results, and AI-assisted quantification of target organ damage.
- Control group: Standard care provided by attending physicians according to routine practice. The digital platform is also installed but limited to home BP recording and automated analysis, without remote monitoring, interactive modules, personalized messaging, laboratory data input, AI-based organ quantification, or risk alerts. Consent forms specify that the control group will not receive enhanced digital interventions.
Pragmatic Digital Health Registry Program (T-888-DIGICARE-Registry)
- Blood Pressure Intervention Logic (per 2022 Taiwan Hypertension Guidelines):
- System prompts physicians to initiate/adjust antihypertensive therapy if average home BP >130/80 mmHg.
- Untreated patients: initiate therapy.
- Poorly controlled patients: increase dosage if average BP 130-139/80-89 mmHg, or add a new agent if >140/90 mmHg.
- If isolated morning BP >130/80 mmHg: shift one antihypertensive agent to bedtime dosing.
- If isolated bedtime BP >130/80 mmHg: switch short-acting agent to long-acting formulation.
- Monthly reminders for patients to perform "722 protocol" home BP monitoring (≥4 days). Automated push notifications are sent if records are insufficient. Notifications are logged for case manager follow-up.
- Lipid Intervention Logic (per 2022 Taiwan Dyslipidemia Guidelines):
- LDL-C >100 mg/dL without complications: initiate moderate-intensity statin.
- Diabetes with LDL-C >70 mg/dL: initiate high-intensity statin or maximally tolerated dose, ± non-statin therapy.
- ASCVD with LDL-C >70 mg/dL: initiate high-intensity statin or maximally tolerated dose, ± non-statin therapy.
- Glycemic Intervention Logic (per ADA Guidelines):
- Abnormal HbA1c within 3 months: ≥6.5%, or insufficient improvement (e.g., >8% without ≥1% reduction, >10% without ≥2% reduction).
- Treatment recommendations:
- HbA1c <9% and drug-naïve: initiate metformin.
- HbA1c ≥9%: initiate dual oral therapy (e.g., metformin + SGLT2i or DPP-4i).
- If uncontrolled after 3 months: add 1-2 oral agents.
- If still uncontrolled: introduce GLP-1 RA or basal insulin.
- If already on injectables but uncontrolled: adjust dose or consider mixed insulin regimen.
- With cardiovascular disease: prioritize SGLT2i or GLP-1 RA.
- Lifestyle Intervention:
- Weekly randomized delivery of short educational messages (CV disease knowledge, medication reminders, nutrition, physical activity).
- Targeted reinforcement for unmet goals (e.g., medication adherence, exercise, diet).
- Patient Interaction Mechanisms:
- 24-hour AI chatbot for health consultation and emergency alerts.
- Integrated digital health records: patients can review longitudinal data on BP, lipids, glucose, renal function, and goal attainment trends.
Randomized Clinical Trial on Optimal Timing of Antihypertensive Medication for Morning Hypertension (DREAM-G)
- Patients perform home BP monitoring per "722 protocol" (≥4 morning and ≥4 evening readings within 7 days) prior to clinic visit.
- Hypertensive patients with morning BP ≥130/80 mmHg (average home BP ≥130/80 mmHg or on antihypertensive therapy) are invited.
- Trial sites include community clinics. Participants are randomized 1:1 to intervention (bedtime dosing) or control (morning dosing).
- Physicians prescribe antihypertensive regimens (CCB, ARB/ACEI, or combinations) aiming to control morning and average BP <130/80 mmHg.
- Objective: Both morning and average blood pressure <130/80 mmHg (722 protocol: at least 4 measurements of morning and average BP within 7 consecutive days)
- Intervention group: stepwise bedtime dosing strategy: ACEI/ARB → CCB → fixed-dose ACEI(ARB)/CCB combination → diuretic → α-blocker → β-blocker → mineralocorticoid receptor antagonist (MRA).
- Control group: morning dosing adjustments.
Adjustment principles:
- If average home BP ≥130/80 mmHg and morning BP ≥130/80 mmHg: both groups escalate therapy.
- If average home BP <130/80 mmHg but morning BP ≥130/80 mmHg: control group maintains regimen; intervention group shifts one agent to bedtime dosing.
Principles of Antihypertensive Medication Adjustment:
Treated HTN Untreated HTN Average Home BP Monitoring (HBPM) HBPM < 130/80 mmHg HBPM ≥ 130/80 mmHg HBPM ≥ 130/80 mmHg Morning Home BP Monitoring (HBPM) HBPM ≥ 130/80 mmHg HBPM ≥ 130/80 mmHg HBPM ≥ 130/80 mmHg Intervention Group Shift one antihypertensive agent from daytime to bedtime dosing Initiate a new antihypertensive agent at bedtime, or adjust the dosage of existing medication Initiate a new antihypertensive agent at bedtime Control Group No dosage adjustment required Initiate a new antihypertensive agent during the daytime, or adjust the dosage of existing medication Initiate a new antihypertensive agent during the daytime
Clinical Assessments:
- Monthly home BP monitoring per "722 protocol," recorded every 2 months until study completion.
- Laboratory and imaging assessments at baseline, and months 2, 4, 6, 12, 14, 16, 20, and 24: complete blood count, ALT, lipid profile, fasting glucose/HbA1c, BUN/creatinine, electrolytes, NT-proBNP, uric acid, UACR, fundus photography, ECG, and BP measurements.
- Detailed schedule provided in trial flowchart (see p.7).
- Conditions
- Microalbuminuria, Microalbuminuria /Creatinine Ratios ACR, Cardiovascular Disease Risk Factor, Cardiovascular Disease Prevention, Digital Medicine, Hypertension
- Being tested
- Interactive digital modules, Antihypertensive Medication Management
- Keywords
- digital medicine, hypertension, home blood pressure monitoring, dyslipidemia, microalbuminuria, diabetes
- Medical subject headings
- Hypertension, Hyperglycemia, Hyperlipidemias, Dyslipidemias, Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Interactive digital modulesBehavioural
Whether the Mobile Digital Health Platform augmented with interactive digital modules improves control rates of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia), target organ damages and cardiovascular outcomes
Antihypertensive Medication ManagementBehavioural
Therapeutic effects of selective nocturnal versus universal morning antihypertensive dosing on morning home blood pressure control and target organ damages
| Study group | Role | What they receive |
|---|---|---|
| Standard care | No intervention | with a mobile digital health platform but no interactive digital modules |
| bedtime dosing | Experimental | Selective nocturnal antihypertensive dosing Receives: Behavioral: Antihypertensive Medication Management |
| Conventional morning dosing | No intervention | Universal morning antihypertensive dosing |
| Degital care | Experimental | With a mobile digital health platform augmented with interactive digital modules Receives: Behavioral: Interactive digital modules |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean home blood pressure <130/80 mmHg.
T-888-DIGICARE study
Measured: 24 months from baseline
LDL-C <100 mg/dL (and <70 mg/dL for patients with diabetes or ASCVD).
T-888-DIGICARE study
Measured: 24 months from baseline
HbA1c <6.5% or a reduction of at least 1% from baseline if baseline HbA1c >8% or at least 2% if baseline HbA1c >10%.
T-888-DIGICARE study
Measured: 24 months from base line
≥30% reduction in urine albumin to creatinine ratio (UACR).
T-888-DIGICARE study
Measured: 24 months from baseline
Improvement in target organ damage (changes in left ventricular mass by AI ECG and in retinal vascular lesions).
T-888-DIGICARE study
Measured: 24 months from baseline
• Morning home systolic and diastolic blood pressure at 6 months.
DREAM-G study
Measured: 6 months
• Change in UACR from baseline to 6 months, as a marker of renal target organ protection.
DREAM-G study
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2026
- Study start5 Feb 2026
- Primary completion5 Feb 2029 (estimated)
- Study completion5 Feb 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MicroalbuminuriaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The first trial (T-888-DIGICARE) will evaluate whether a mobile digital health platform augmented with interactive digital modules can more effectively achieve the "888" targets for prevention and treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia). The second trial (DREAM-G) will use the same mobile health delivery model to investigate whether the timing of antihypertensive medication administration (nocturnal versus morning dosing) differentially affects patients with poor morning home blood pressure control.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 4,162 participants (estimated)
Sponsor and investigators
- Lead sponsor
- New Taipei City Medical Association
- Sponsor type
- University, hospital or other
- Collaborators
- National Taiwan University
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07588256
- Sponsor's protocol ID
- T888-DIGICARE-DREAM
- Acronym
- DIGICARE-DREAM
- Status last verified
- May 2026
- First submitted
- 27 Apr 2026
- Last updated
- 14 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- New Taipei City 888 Digital Medical AI Platform for the Prevention and Treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia) and Cardio-Renal-Vascular Diseases: Validation and Implementation Through Large-Scale Cluster Randomized Clinical Trials: T-888-DIGICARE-DREAM
- ClinicalTrials.gov ID
- NCT07588256
- Acronym / sponsor ID
- DIGICARE-DREAM / T888-DIGICARE-DREAM
- Conditions
- Microalbuminuria, Microalbuminuria /Creatinine Ratios ACR, Cardiovascular Disease Risk Factor, Cardiovascular Disease Prevention, Digital Medicine, Hypertension
- Keywords
- digital medicine, hypertension, home blood pressure monitoring, dyslipidemia, microalbuminuria, diabetes
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 4,162 participants (estimated)
- Lead sponsor
- New Taipei City Medical AssociationUniversity, hospital or other
- Collaborators
- National Taiwan University
- Study start
- 5 Feb 2026 (actual)
- Primary completion
- 5 Feb 2029 (estimated)
- Study completion
- 5 Feb 2029 (estimated)
- First posted
- 14 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Non-communicable diseases (NCDs), or chronic diseases, are a major public health burden globally and in Taiwan, and control of the "three highs" (hypertension, dyslipidemia, and hyperglycemia) is a national priority. Nearly half of the 10 leading causes of death in Taiwan are directly or indirectly related to atherosclerotic cardiovascular disease (ASCVD), for which hypertension, dyslipidemia, and abnormal blood glucose are the major risk factors. National health insurance data indicate that over 70% of middle-aged and older adults have at least one of these chronic conditions. Early stages are often asymptomatic, and inadequate control may lead to complications of cardiovascular disease, stroke, renal vascular disease, and retinopathy, causing irreversible organ damage and death.
For blood pressure, large clinical trials such as SPRINT and STEP have shown that targeting systolic blood pressure below 130 mmHg significantly reduces ASCVD events. For LDL cholesterol, "the lower, the better" applies, with guideline-recommended LDL-C targets determined by baseline ASCVD risk, with levels below 55 mg/dL for very high-risk patients. For diabetes, treatment goals generally include fasting plasma glucose below 130 mg/dL and glycated hemoglobin (HbA1c) below 7%.
Although antihypertensive therapy has been proven effective in preventing cardiovascular disease and chronic kidney disease attributable to hypertension, fewer than one-third of patients receiving antihypertensive medications achieve current guideline-recommended blood pressure targets. No randomized clinical trial to date has used home blood pressure as the primary therapeutic reference. Moreover, long-term evidence is lacking regarding the organ-protective effects of strategies targeting morning hypertension and of bedtime dosing regimens. Although the TIME study is currently the largest and longest-followed trial addressing dosing time, its bedtime-dosing arm was not specifically targeted to patients with morning hypertension. Therefore, we propose a clinical trial to investigate management strategies for morning hypertension. Aligned with the 2022 Taiwan Hypertension Guidelines, we will employ the "722 protocol" for home blood pressure monitoring and enroll patients with morning home blood pressure ≥130/80 mmHg to compare selective nocturnal administration of antihypertensive agents versus exclusive morning dosing, assessing differences in morning home blood pressure control rates, end-organ damage, and atherosclerotic cardiovascular disease (ASCVD) events.
This project will implement two large-scale cluster-randomized clinical trials within the New Taipei City healthcare network. The first trial (T-888-DIGICARE) will evaluate whether a mobile digital health platform augmented with interactive digital modules can more effectively achieve the "888" targets for prevention and treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia). The second trial (DREAM-G) will use the same mobile health delivery model to investigate whether the timing of antihypertensive medication administration (nocturnal versus morning dosing) differentially affects patients with poor morning home blood pressure control. Beyond generating rigorous evidence through a novel clinical approach, this program is expected to have substantial global clinical impact and to showcase Taiwan's healthcare capabilities internationally. Operational challenges encountered and solutions developed during the trials will also provide critical feasibility data for the concurrent real-world implementation registry (T-888-DIGICARE-Registry). The registry will run in parallel with the cluster trials and will enroll individuals who decline trial participation at baseline as well as participants after trial completion, thereby serving as a continuity and real-world evidence platform.
Detailed description
Participants identified through the 888 screening program with at least one abnormal value will be invited for group allocation. Home blood pressure measurement will be performed according to the "722 protocol." If morning home BP ≥130/80 mmHg (average home BP ≥130/80 mmHg or already receiving antihypertensive therapy), participants will be invited to join the randomized clinical trial DREAM-G, investigating optimal timing of antihypertensive medication for morning hypertension. All other participants will be invited to the randomized clinical trial T-888-DIGICARE, evaluating care intervention via a mobile smart healthcare platform. Those not enrolled will be invited to participate in the pragmatic digital health registry program T-888-DIGICARE-Registry.
Execution methods and procedures for these three large-scale clinical trials are as follows:
Randomized Clinical Trial of Mobile Smart Healthcare Platform Intervention (T-888-DIGICARE)
- Randomization Unit: Participating primary care clinics. Each clinic must complete informed consent and enrollment preparation prior to participation.
- Randomization Method: Computer-generated block randomization, stratified by clinic location. Stratification is based on the median household disposable income across the 29 administrative districts of New Taipei City, categorized into three socioeconomic tiers. Clinics are randomized within each tier to minimize confounding by socioeconomic status on health behaviors and healthcare accessibility, and to facilitate future policy expansion in lower-income regions.
- Given the practical nature of digital platform implementation, blinding of physicians and patients is not feasible. Therefore, a single-blind design is adopted: investigators responsible for data aggregation and statistical analysis of primary and secondary endpoints remain blinded to clinic allocation, reducing analytic bias.
- Intervention Measures:
- Years 1-5 (Trial duration: 3 years enrollment, 2 years follow-up)
- Intervention group: Comprehensive integration of the "888 Digital Management Platform" into participating clinics and patient mobile devices. Features include app-based interactive modules, personalized message push notifications, input of "three-high" (hypertension, hyperlipidemia, hyperglycemia) test results, and AI-assisted quantification of target organ damage.
- Control group: Standard care provided by attending physicians according to routine practice. The digital platform is also installed but limited to home BP recording and automated analysis, without remote monitoring, interactive modules, personalized messaging, laboratory data input, AI-based organ quantification, or risk alerts. Consent forms specify that the control group will not receive enhanced digital interventions.
Pragmatic Digital Health Registry Program (T-888-DIGICARE-Registry)
- Blood Pressure Intervention Logic (per 2022 Taiwan Hypertension Guidelines):
- System prompts physicians to initiate/adjust antihypertensive therapy if average home BP >130/80 mmHg.
- Untreated patients: initiate therapy.
- Poorly controlled patients: increase dosage if average BP 130-139/80-89 mmHg, or add a new agent if >140/90 mmHg.
- If isolated morning BP >130/80 mmHg: shift one antihypertensive agent to bedtime dosing.
- If isolated bedtime BP >130/80 mmHg: switch short-acting agent to long-acting formulation.
- Monthly reminders for patients to perform "722 protocol" home BP monitoring (≥4 days). Automated push notifications are sent if records are insufficient. Notifications are logged for case manager follow-up.
- Lipid Intervention Logic (per 2022 Taiwan Dyslipidemia Guidelines):
- LDL-C >100 mg/dL without complications: initiate moderate-intensity statin.
- Diabetes with LDL-C >70 mg/dL: initiate high-intensity statin or maximally tolerated dose, ± non-statin therapy.
- ASCVD with LDL-C >70 mg/dL: initiate high-intensity statin or maximally tolerated dose, ± non-statin therapy.
- Glycemic Intervention Logic (per ADA Guidelines):
- Abnormal HbA1c within 3 months: ≥6.5%, or insufficient improvement (e.g., >8% without ≥1% reduction, >10% without ≥2% reduction).
- Treatment recommendations:
- HbA1c <9% and drug-naïve: initiate metformin.
- HbA1c ≥9%: initiate dual oral therapy (e.g., metformin + SGLT2i or DPP-4i).
- If uncontrolled after 3 months: add 1-2 oral agents.
- If still uncontrolled: introduce GLP-1 RA or basal insulin.
- If already on injectables but uncontrolled: adjust dose or consider mixed insulin regimen.
- With cardiovascular disease: prioritize SGLT2i or GLP-1 RA.
- Lifestyle Intervention:
- Weekly randomized delivery of short educational messages (CV disease knowledge, medication reminders, nutrition, physical activity).
- Targeted reinforcement for unmet goals (e.g., medication adherence, exercise, diet).
- Patient Interaction Mechanisms:
- 24-hour AI chatbot for health consultation and emergency alerts.
- Integrated digital health records: patients can review longitudinal data on BP, lipids, glucose, renal function, and goal attainment trends.
Randomized Clinical Trial on Optimal Timing of Antihypertensive Medication for Morning Hypertension (DREAM-G)
- Patients perform home BP monitoring per "722 protocol" (≥4 morning and ≥4 evening readings within 7 days) prior to clinic visit.
- Hypertensive patients with morning BP ≥130/80 mmHg (average home BP ≥130/80 mmHg or on antihypertensive therapy) are invited.
- Trial sites include community clinics. Participants are randomized 1:1 to intervention (bedtime dosing) or control (morning dosing).
- Physicians prescribe antihypertensive regimens (CCB, ARB/ACEI, or combinations) aiming to control morning and average BP <130/80 mmHg.
- Objective: Both morning and average blood pressure <130/80 mmHg (722 protocol: at least 4 measurements of morning and average BP within 7 consecutive days)
- Intervention group: stepwise bedtime dosing strategy: ACEI/ARB → CCB → fixed-dose ACEI(ARB)/CCB combination → diuretic → α-blocker → β-blocker → mineralocorticoid receptor antagonist (MRA).
- Control group: morning dosing adjustments.
Adjustment principles:
- If average home BP ≥130/80 mmHg and morning BP ≥130/80 mmHg: both groups escalate therapy.
- If average home BP <130/80 mmHg but morning BP ≥130/80 mmHg: control group maintains regimen; intervention group shifts one agent to bedtime dosing.
Principles of Antihypertensive Medication Adjustment:
Treated HTN Untreated HTN Average Home BP Monitoring (HBPM) HBPM < 130/80 mmHg HBPM ≥ 130/80 mmHg HBPM ≥ 130/80 mmHg Morning Home BP Monitoring (HBPM) HBPM ≥ 130/80 mmHg HBPM ≥ 130/80 mmHg HBPM ≥ 130/80 mmHg Intervention Group Shift one antihypertensive agent from daytime to bedtime dosing Initiate a new antihypertensive agent at bedtime, or adjust the dosage of existing medication Initiate a new antihypertensive agent at bedtime Control Group No dosage adjustment required Initiate a new antihypertensive agent during the daytime, or adjust the dosage of existing medication Initiate a new antihypertensive agent during the daytime
Clinical Assessments:
- Monthly home BP monitoring per "722 protocol," recorded every 2 months until study completion.
- Laboratory and imaging assessments at baseline, and months 2, 4, 6, 12, 14, 16, 20, and 24: complete blood count, ALT, lipid profile, fasting glucose/HbA1c, BUN/creatinine, electrolytes, NT-proBNP, uric acid, UACR, fundus photography, ECG, and BP measurements.
- Detailed schedule provided in trial flowchart (see p.7).
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 4
- Model description
- The first trial (T-888-DIGICARE) will evaluate whether a mobile digital health platform augmented with interactive digital modules can more effectively achieve the "888" targets for prevention and treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia). The second trial (DREAM-G) will use the same mobile health delivery model to investigate whether the timing of antihypertensive medication administration (nocturnal versus morning dosing) differentially affects patients with poor morning home blood pressure control.
| Arm | Type | Receives |
|---|---|---|
| Standard care | No intervention | –with a mobile digital health platform but no interactive digital modules |
| bedtime dosing | Experimental | Behavioral: Antihypertensive Medication ManagementSelective nocturnal antihypertensive dosing |
| Conventional morning dosing | No intervention | –Universal morning antihypertensive dosing |
| Degital care | Experimental | Behavioral: Interactive digital modulesWith a mobile digital health platform augmented with interactive digital modules |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (41 listed)
- I.T-888-DIGICARE：
- Eligible participants must meet the definition of hypertension and at least one of the following chronic (non-hypertensive) conditions:
- Hypertension
- Hyperlipidemia
- Diabetes Mellitus
Key exclusion criteria (9 listed)
- T-888-DIGICARE
- Symptomatic heart failure (New York Heart Association functional class II-IV)
- End-stage renal disease requiring long-term dialysis
- Pregnant women or those planning pregnancy
- DREAM-G:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Interactive digital modulesWhether the Mobile Digital Health Platform augmented with interactive digital modules improves control rates of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia), target organ damages and cardiovascular outcomes | Behavioural | Degital care |
| Antihypertensive Medication ManagementTherapeutic effects of selective nocturnal versus universal morning antihypertensive dosing on morning home blood pressure control and target organ damages | Behavioural | bedtime dosing |
Primary outcome
Mean home blood pressure <130/80 mmHg.
Time frame: 24 months from baseline
T-888-DIGICARE study
LDL-C <100 mg/dL (and <70 mg/dL for patients with diabetes or ASCVD).
Time frame: 24 months from baseline
T-888-DIGICARE study
HbA1c <6.5% or a reduction of at least 1% from baseline if baseline HbA1c >8% or at least 2% if baseline HbA1c >10%.
Time frame: 24 months from base line
T-888-DIGICARE study
≥30% reduction in urine albumin to creatinine ratio (UACR).
Time frame: 24 months from baseline
T-888-DIGICARE study
Improvement in target organ damage (changes in left ventricular mass by AI ECG and in retinal vascular lesions).
Time frame: 24 months from baseline
T-888-DIGICARE study
• Morning home systolic and diastolic blood pressure at 6 months.
Time frame: 6 months
DREAM-G study
• Change in UACR from baseline to 6 months, as a marker of renal target organ protection.
Time frame: 6 months
DREAM-G study
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2026.
- Individual participant dataSharing planned: No
Related trials for Microalbuminuria
Not yet recruitingObservational study
Diastolic Dysfunction and Pulmonary Hypertension in T2DM With Microalbuminuria
Diabetes Mellitus Type 2
RecruitingPhase 1
Time Restricted Eating in Patients With Microalbuminuria
Type 2 Diabetes Mellitus (T2DM), Time Restricted Eating
RecruitingPhase 4
ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases
Hypertensive Nephropathy, Auto Immune Disorders
Enrolling by invitationObservational study
Risk Factors at Chronic Non-communicable Diseases in People of Working Age
Chronic Non-communicable Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Tzung-Dau Wang Co-Principal Investigator contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Interactive digital modules and Antihypertensive Medication Management in people with Microalbuminuria and Microalbuminuria /Creatinine Ratios ACR, run by New Taipei City Medical Association at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 41 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hung-Shun Yen Principal Investigator (886-22994-2075, usmg@usmg.com.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean home blood pressure <130/80 mmHg. (time frame: 24 months from baseline). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2026.